Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease

In patients with NAFLD and diabetes, metformin use was associated with a 22% lower risk of hepatocellular carcinoma compared with no diabetes medication, independent of glycemic control.

Effect: improvement; HR 0.77; CI: 95% CI 0.65-0.90

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

In patients with NAFLD and diabetes, maintaining adequate glycemic control (HbA1c <7% for >80% of time) was associated with a 32% lower risk of hepatocellular carcinoma, independent of diabetes medica

Effect: improvement; HR 0.68; CI: 95% CI 0.60-0.77

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38